Clinical Trials Directory

Trials / Completed

CompletedNCT01645800

Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study

Effects of Lysozyme On Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
408 (actual)
Sponsor
Eisai Co., Ltd. · Industry
Sex
All
Age
20 Years – 84 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.

Conditions

Interventions

TypeNameDescription
DRUGLysozyme hydrochlorideLYL 90mg capsule: Three times daily for 52 weeks.
DRUGPlaceboMatching Placebo capsule: Three times daily for 52 weeks.

Timeline

Start date
2012-08-01
Primary completion
2015-01-01
Completion
2015-03-01
First posted
2012-07-20
Last updated
2015-10-21

Locations

25 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01645800. Inclusion in this directory is not an endorsement.

Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Stu (NCT01645800) · Clinical Trials Directory